Your SlideShare is downloading. ×
What To Look For In Peregrine Pharmaceuticals Q2 Earnings
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

What To Look For In Peregrine Pharmaceuticals Q2 Earnings

2,973
views

Published on

Peregrine Pharmaceuticals (NASDAQ: PPHM) will report second quarter results after the bell today and given that shares have done little this year, investors are right to be looking for clues as to …

Peregrine Pharmaceuticals (NASDAQ: PPHM) will report second quarter results after the bell today and given that shares have done little this year, investors are right to be looking for clues as to whether the company's promising immunotherapy for cancer may make an impact.
In the following slideshow, I offer insight into Peregrine's bavituximab and outline key questions I'll be looking to have answered during the second quarter conference call.

Published in: Health & Medicine

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
2,973
On Slideshare
0
From Embeds
0
Number of Embeds
15
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. What To Look For in Peregrine’s Q2 Earnings
  • 2. Big Bet on Immunotherapy • Peregrine is developing bavituximab – Phase 3 trial in second-line non-small cell lung cancer. – Fast track designation. – Positive results in phase 2 trials.
  • 3. Bavituximab • Bavituximab – Targets PS, a highly immunosuppressive molecule. • PS flips to the outside of cancerous cells. – Protects cancerous cells from the immune system. – Bavituximab blocks PS’ immunosuppressive signal. • Makes cancer cells susceptible to the immune system.
  • 4. Bavituximab • Bavituximab phase 2 results – Improved median overall survival. • Dosed alongside docetaxel. • 11.7 months versus 7.3 months on docetaxel alone. • Well tolerated with no significant differences in adverse events between the trial arms.
  • 5. Bavituximab • Phase 3 enrollment – Look for an update on enrollment. • Trial began in December 2013. • Planned enrollment of 600 patients. • Estimated primary completion date of December 2016.
  • 6. Cash burn rate • Cash climbed heading into phase 3. – How quickly is the phase 3 trial drawing down cash? • Quarterly SG&A of $4.56 million in Q1. • Quarterly R&D of $6.64 million in Q1. • Preferred stock offering brings cash to $79.7 million on February 28th .
  • 7. Updates on Combinations • Peregrine is launching trials studying bavituximab alongside other top-selling drugs. – Alongside paclitaxel in HER2 negative breast cancer. – Alongside Nexavar in liver cancer. – Alongside carboplatin and pemetrexed in untreated NSCLC. – In April, initiated phase 1b trial for use alongside Bristol-Myers Yervoy in advanced melanoma.
  • 8. Fool-worthy thoughts – Is the second-line NSCLC phase 3 trial enrollment progressing as hoped? – Is the company’s cash position stable or falling? – Are there updates to the combination therapy programs? • PD-1 and CTLA-4 pathways.
  • 9. Leaked: This coming blockbuster will make every biotech jealous
  • 10. Leaked: This coming blockbuster will make every biotech jealous